

DATA WAREHOUSE: A VALUED COALITION STRATEGY

Gaye Fortner, HC21 Solutions
GPBCH
JULY 14, 2015




HISTORY OF HC21 DATA WAREHOUSE

- Spring 2004: Data warehouse discussion begins
- 2005: Vendor selection and claims collection including 3 years backload
- 2009: Expands data collection to including biometric, LTD
- 2012: Transition from vendor to in-house programmable database
- 2013: Report Dashboards
- 2015: Integrate and analyze worker's comp data.



DATA INTEGRATION


- Health and lifestyle risks
- Conditions and diagnoses
- Medical claims trends
- Rx claims trends
- Gaps in care
- Program encounters
- Leave of absence
- Presenteeism
- Workers comp





HC21 DATA INTEGRATOR DELIVERABLES

- Web-based 'Dashboards'
 - Monthly Standard Reports
 - DPP Dashboard
 - Specialty Dashboard



Generic Utilization


Preventive

Mammography

Preventive Visits



CEO/CFO FOCUS






CEO/CFO FOCUS


COST & UTIL


HEALTH RISK





BENEFIT MANAGER FOCUS








INDIVIDUAL LEVEL RISK STRATIFICATION SAMPLE UTILIZED FOR BASELINE AND INTERVENTION TARGETING

	Participant Risk Summary - Results as of: February, 2012									Risk Ranges:															
		randicipant mak summary mesants as or.											Biom	etric	Risk Ran	ge High Risk									
		Num	ber o	f Par	rticin	pants	(incl	udes	pre	gnand	cies):				74	17					Total	Chole:	5	> 200	> 200
												LDL			> 100	> 160									
													HDL	_		< 40	< 40								
Г		Danulation Bisk Community										Trigly			> 150 > 100	> 200 > 126									
		Population Risk Summary:									SBP	J3E		> 120	> 139										
	Chol LDL HDL Chol/ Trig Gluc						: 5	ВР	DBP	BN	И				DBP			> 80	> 89						
										HDL											BMI			> 24.99	> 30
					ŀ	745	709	74	10	740	744	737	-	38	770	74					Chol			> 4.5	> 4.5
		Ans	wered	1		/45	709	/-	+0	740	/44	/3/	/	30	738	/-	Ю					nol Drir			> 13
		Ave	Metr	ic Val	ue	193.9	115.8	3 4	9	4.6	152	97	1	24	77	2	9					o Days th Perc	•	k <5 Fair	< 3 Poor
L								_				_	_									tn Perci		Neutra	and the second s
	(Cholesterol, HDL, and Chol/HDL are counted as separate risks in attached report)											21128126													
T										Hgt In		-					HTN	_	Other Cond	Smoker	Smoki	Alaab	Candia	Constant to state	Life Satisfaction
Ag	ge Sex	LDL	Choi		/HDL	_	Gluc	SBP	DBP	Hgt in	Lbs	BMI	High Risk Bio	DIA	ASIH	CAD	HIN	LIP	Other Cond	Smoker	ess	Alcon	Cardio	Overall Health	Life Satisfaction
					,						203		810								Tobac				
4	9 M	231	330	33	10	330	96	160	100	67	212	33.2	8				~	~		Υ	Υ	0	7	Good	Strongly Agree
5	1 M		226	27	8.4	461	425	152	92	69	318	47.0	8	~								0	2	Good	Agree
3	7 M		285	19	15	1321	106	158	100	74	317	40.7	7	✓		✓	~	✓		Υ		0	0	Good	Strongly Agree
4	8 M	142	229	46	5	204	128	150	106	73	254	33.5	7									14	2	Fair	Neutral
3	6 M	133	219	30	7.3	281	162	126	90	76	275	33.5	7									0	3	Good	Agree
4	4 M		205	41	5	564	155	186	114	69	213	31.5	7				y			Υ			7	Good	
4	4 M	128	213	32	6.7	264	92	132	96	67	216	33.8	6					~	chronic pain	Υ		2	1	Fair	
5	1 F	188	237	33	7.2	270	132	138	80	68	158	24.0	6				~	~				2	7	Good	
4	9 F	179	312	59	5.3	470	86	150	84	65	200	33.3	6							Υ		0	2	Fair	Neutral
4	1 M	118	202	38	5.3	231	366	130	76	71	334	46.6	6	~			~	~							
5	0 M	137	221	37	6	235	76	148	96	73	187	24.7	6						HTN - new onset			2	3	Excellent	Strongly Agree
4	5 F	147	212	34	6.2	157	231	142	80	62	242	44.3	6	~			~	~				2	1	Poor	Strongly Agree
4	4 M		246	21	12	459	125	156	88	69	211	31.2	6				~				Υ	3	0	Fair	Neutral
4	3 M		298	45	6.6	527	152	170	86	64	175	30.0	6	~			~	~			Υ	0	4	Good	Strongly Agree
6	4 M	132	224	37	6.1	277	199	136	80	71	304	42.4	6	~			~	~		Υ		0	3	Excellent	Strongly Agree




CONDITION SPECIFIC

DIABETES PREVENTION





CONDITION SPECIFIC DIABETES PREVENTION





HC21 DATA INTEGRATOR DELIVERABLES


Ad hoc analyses and Program Evaluations


• For example, Specialty Rx Top 4 Narcotic Drugs by quarter Narcotic Utilization Reference Pricing Program Evaluation (On Site Clinic) PA Program Description Services MIN MAX REF \$ SAVINGS \$500.00 \$475.00 MRI – Head & Neck \$10,01 CT – Head and Neck \$225.27 \$237.50 \$6,668 MRI – Spine/Cerv 36 \$350.00 \$581.92 \$308.75 \$5,21 MRI – Spine/Lumb 56 \$328.03 \$4,070 \$380.00 PMPM of Specialty RX PBM Costs CT - Abdomen \$3,404 \$21.43 Readiness to Change Trending Begin 100% End 80% \$14.95 4096 \$10.42 \$10 TOTAL Action Unsure that a Person has Taking positive Actively making Made the Have Arrived, No. Stage problem even admitted to the modifications to temptations and knows that it is strong. Lacking confident there some confidence 10/2012 - 09/2013




SPECIALTY RX DASHBOARD

% of Mbrs with a Specialty PBM Script






% Cost of Total PBM (Mbrs with Specialty PBM Script)




PBM Specialty vs Traditional MbrShare






SPECIALTY RX DASHBOARD

Specialty RX PBM and Medical as a % of All Claims




Specialty RX PBM vs Medical



PBM Specialty RX Costs and % of Total PBM Cost



PBM Specialty RX Cost per Day Supply





SPECIALTY RX TOP 10

Top 10 MPC for Specialty RX (PBM and Medical)

Condition	Paid
Neoplasms	\$195,838
Diseases of the nervous system and sense organs	\$67,474
Diseases of the digestive system	\$46,543
Diseases of the musculoskeletal system and connective tissue	\$38,584
Endocrine; nutritional; and metabolic diseases and immunity disorders	\$18,349
Diseases of the blood and blood-forming organs	\$17,721
Diseases of the circulatory system	\$9,74%
Complications of pregnancy; childbirth; and the puerperium	\$9,542
Diseases of the skin and subcutaneous tissue	\$2,300
Infectious and parasitic diseases	\$1,909

Top 5 Pharmacies Filling Specialty Scripts

Pharmacy ID	Paid	Specialty Rx Scripts	Cost/Script
263361	\$66,264	8	\$8,283
443582	\$50,759	5	\$10,152
444048	\$24,199	10	\$2,420
395889	\$15,952	6	\$2,659
442868	\$11,972	3	\$3,991

Top 10 Conditions for Specialty RX (PBM and Medical)

Condition	Paid
Cancer of bronchus; lung [19.]	\$119,632
Other nervous system disorders [95.]	\$66,264
Lower gastrointestinal disorders	\$46,543
Malignant neoplasm without specification of site [43.]	\$42,747
Non-traumatic joint disorders	\$38,584
Maintenance chemotherapy; radiotherapy [45.]	\$28,229
Other endocrine disorders [51.]	\$16,836
Conquiation and hemorrhagic disorders [62.]	\$10,051
Diseases of arteries; arterioles; and capillaries	\$9,743
Contraceptive and procreative management [176.]	\$9,542

Top 5 Prescribers of Specialty Scripts

DEAPrescriber IDRef	Paid	Specialty Rx Scripts	Cost/Script
DEANumber	\$48,675	6	\$8,112
DEANumber	\$41,654	4	\$10,414
DEANumber	\$24,199	10	\$2,420
DEANumber	\$17,590	2	\$8,795
DEANumber	\$15,952	6	\$2,659



SPECIALTY RX TOP 10

Top PBM Specialty Scripts


Drug Name Scripts Paid Paid/Script **Xyrem** 8 \$66,264 \$8,283 Abilify 6 \$55,888 \$9,315 Enbrel SureClick 10 \$24,199 \$2,420 Cimzia \$15,952 \$2,659 6 Enbrel 3 \$11,972 \$3,991 Fondaparinux Sodium \$9,743 4 \$2,436 \$8,075 \$8,075 Cimzia Starter Kit 1 Enoxaparin Sodium \$8,011 \$1,662 5 \$6,691 \$3,346 Makena 2 Zyvox 1 \$4,785 \$4,785 Humira Pen \$2,413 \$2,413 Albenza \$1,909 \$1,909 Absorica \$1,470 \$1,470

Top Medical Specialty Scripts

Drug Name	Scripts	Paid	Paid/Script
PACLITAXEL PROTEIN BOUND	5	\$61,905	\$12,381
PORFIMER SODIUM INJECTION	1	\$51,265	\$51,265
INJECTION, PEGFILGRASTIM 6MG	7	\$48,437	\$6,920
INJECTION INFLIXIMAB, 10 MG	12	\$46,543	\$3,879
SUPPRELIN LA IMPLANT	1	\$16,836	\$16,836
ROMIPLOSTIM INJECTION	6	\$10,051	\$1,675
GEMCITABINE HCL INJECTION	2	\$9,822	\$4,911
DARBEPOETIN ALFA, NON- ESRD	2	\$7,670	\$3,835
PALONOSETRON HCL	7	\$7,444	\$1,063
LEVONORGESTREL- RELEASING INTRAUTERI	9	\$7,444	\$827
FOSAPREPITANT INJECTION	7	\$5,240	\$749
IVIG NON-LYOPHILIZED, NOS	1	\$4,857	\$4,857
BEVACIZUMAB INJECTION	1	\$2,919	\$2,919
DEXAMETHASONE INTRA IMPLANT	1	\$1,513	\$1,513
LEUPROLIDE ACETATE (FOR DEPOT SUSPE	1	\$1,349	\$1,349




SPECIALTY RX HEP C MODEL






REFERENCE PRICING



Description	Services	MIN	MAX	REF \$	SAVINGS
MRI – Head & Neck	46	\$450.00	\$884.60	\$475.00	\$10,018
CT – Head and Neck	21	\$225.27	\$582.00	\$237.50	\$6,668
MRI – Spine/Cerv	36	\$300.00	\$581.92	\$308.75	\$5,217
MRI – Spine/Lumb	56	\$328.03	\$539.21	\$380.00	\$4,070
CT - Abdomen	24	\$271.39	\$495.05	\$308.75	\$3,404



NARCOTIC UTILIZATION





PROGRAM EVALUATION

Identify Study Populations (participant and non-participant)

Evaluate Enrollment/Engagement

Evaluate Clinical Outcomes

Evaluate Utilization Outcomes (rx, medical, ER, hospital)


Evaluate Financial Outcomes (ROI)


Evaluate Humanistic Outcomes (life quality impacts)


Evaluate Socio-Economic Outcomes (absenteeism, presenteeism, short-term leave, return to work, productivity)




PROGRAM EVALUATION REPORTING SAMPLES













PROGRAM EVALUATION REPORTING SAMPLES








PROGRAM EVALUATION REPORTING SAMPLES

Productivity Cost Savings*:

\$78K annually

\$156K program period

			Pgrm	Annual
		Baseline	Annual	Leave
		Leave	Leave	Hrs
Conditions	Count	Hrs	Hrs	Variance
1	82	73	58	-15
2	95	96	77	-19
3	50	99	81	-18
4	10	132	84	-48



^{*} Based on annual average per hour wages and volume of productivity hours 'saved'